News

07/04/2021
Risks associated with COVID-19 in pregnancy.

Risks associated with COVID-19 in pregnancy.

This international cohort study (18 countries) conducted from March to October 2020, evaluated in more than 700 pregnant women with a COVID-19 diagnosis and 1400 pregnant women without a COVID-19 diagnosis, the risks associated with COVID-19 infection on maternal and neonatal morbidity. Women with COVID-19 diagnosis were at higher risk for preeclampsia/eclampsia (relative risk [RR], 1.76; 95% CI, 1.27-2.43), severe infections (RR, 3.38; 95% CI, 1.63-7.01), intensive care unit admission (RR, 5.04; 95% CI, 3.13-8.10), maternal mortality (RR, 22.3; 95% CI, 2.88-172), preterm birth (RR, 1.59; 95% CI, 1.30-1.94), severe neonatal morbidity index (RR, 2.66; 95% CI, 1.69-4.18), and severe perinatal morbidity and mortality index (RR, 2.14; 95% CI, 1.66-2.75). Asymptomatic women with COVID-19 diagnosis remained at higher risk only for maternal morbidity and preeclampsia. Cesarean delivery (RR, 2.15; 95% CI, 1.18-3.91) but not breastfeeding (RR, 1.10; 95% CI, 0.66-1.85) was associated with increased risk for neonatal test positivity.
Conclusions: In this multinational cohort study, COVID-19 in pregnancy was associated with consistent and substantial increases in severe maternal morbidity and mortality and neonatal complications.

Villar J, et al. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021 Apr 22:e211050. 

06/16/2021
We are hiring a Quality Engineer

We are hiring a Quality Engineer

Missions:

- Ensuring, optimizing and maintaining the requirements of the Quality System in compliance with the regulations and standards in force in Europe: ISO 9001:2015, ISO 14 001:2015, standards CRB NF S96-900
- Making sure the QMS stays relevant by ensuring it evolves with the firm.
- Leading Process and Management Reviews: ensuring that the Quality System performs properly, proposing and monitoring the Continuous Improvement Plan.
- Planning and carrying out internal and external audits.
- Actively participating in the audits and inspections carried out by the relevant authorities.
Location: Post based in Évry (Paris region)
Business sector: Biotechnologies
Type of contract: Permanent
Educational level: Masters
Availability: As soon as possible

Expected salary: To be determined, based on professional profile
Qualifications and experience:
- Candidates must have at least 3 years’ experience in QMS
- Familiarity with an L2 laboratory, cleanrooms, etc.
- Due to the company’s international standing, a good level of oral and written English is required.

Deadline for applications: 15 July 2021

Applications to be sent to: jobs@abcell-bio.com 

Further information at ABCell-Bio - Ingénieur Qualité (H/F) - Genopole

05/18/2021
Ex vivo expansion of hematopoietic progenitors: interest of a new bioactive peptide.

Ex vivo expansion of hematopoietic progenitors: interest of a new bioactive peptide.

Although umbilical cord blood (UCB) is a promising source of Hematopoietic stem and progenitor cells (HSPCs), the low dose of HSPCs in these preparations limits their use, prompting need for ex vivo HSPC expansion. This study reports the development of a bioactive peptide named SL-13R, the design of which was originally derived from sequence of the extracellular domain of Delta-like homologue 1 (DLK1) protein, expressed on hepatoblasts. UCB HSPCs were cultured with SL-13R in combination with hematopoietic cytokines under xeno-free conditions. SL-13R enhanced ex vivo expansion of UCB HSPCs without loss of long-term reconstitution ability. Transplantation of cells cultured with SL-13R into immunodeficient NOD/Shi-scid/IL-2R knockout mice confirmed that they possess long-term reconstitution and self-renewal abilities.

As the specialist in the production of hematopoietic progenitors, Abcell-bio is able to provide large quantities of CD34+ cells from a single healthy donor, certifying their purity and viability.

Nii T, Konno K, Matsumoto M, Bhukhai K, Borwornpinyo S, Sakai K, Hongeng S, Sugiyama D. The Bioactive Peptide SL-13R Expands Human Umbilical Cord Blood Hematopoietic Stem and Progenitor Cells In Vitro. Molecules. 2021 Apr 1;26(7):1995. doi: 10.3390/molecules26071995. 

02/02/2021
We are hiring a cell culture technician

We are hiring a cell culture technician

Abcell-bio is searching for a talented and dedicated cell culture technicians who would become part of our production unit. The candidates will be responsible for isolating our main product, hematopoietic stem cells.

 

Responsibilities:

  • Isolate primary cells proposed by Abcell-bio, especially CD34+ hematopoietic stem cells from cord blood under controlled atmosphere.
  • Follow Standard Operating Procedures (SOPs) to ensure product specifications are met.
  • Ensure that quality controls and traceability of the produced batches are in accordance with Abcell-bio standards.
  • Participate in the daily laboratory life.
  • Respect the health and safety rules of the laboratory.

Qualifications:

  • Training : HND / Professional bachelor’s degree in biotechnology (bac + 2/3).
  • You have knowledge in the field of mammalian cell culture (preferably extensive experience from working in a L2 environment).
  • You have worked with mammalian cell analysis and characterization techniques such as flow cytometry and IHC.
  • Given the international environment of the company, a good level of written English is desirable.

Salary according to the experience and profile. Positions to be filled as soon as possible

Application deadline: October 1st 2021

For submission of applications (and further inquiries if needed): jobs@abcell-bio.com

01/04/2021
Human Umbilical Vein Endothelial Cell Support Bone Formation of Adipose-Derived Stem Cell

Human Umbilical Vein Endothelial Cell Support Bone Formation of Adipose-Derived Stem Cell

This study aims at investigating the co-implantation of human adipose-derived stem cells (ADSCs) after osteogenic differentiation and human umbilical vein endothelial cells (HUVECs) embedded in a vascularized osteogenic matrix of hydroxyapatite (HAp) ceramic for bone tissue engineering. Interestingly, the implantation of HUVEC led to bone formation, suggesting that implanted HUVEC stimulated bone formation. This result may be caused the ability of the extracellular matrix from HUVEC to stimulate the osteogenic differentiation of osteoprogenitor cells. The implantation of osteogenically differentiated ADSC led to higher bone formation than the implantation of HUVEC. But only the co-implantation of ADSC and HUVEC led to a statistically significant larger bone area compared to the other cell-containing groups. This supports the results of earlier studies which showed that endothelial cells stimulate proliferation, cell survival and osteogenic differentiation of osteoprogenitor cells in vitro and bone formation in vivo. Hence, the co-implantation of differentiated ADSCs with HUVECs may therefore be considered as a promising approach for bone tissue engineering. As the specialist in the production of endothelial cells, Abcell-bio is your partner to enable your research.

 Winkler S, et al. Support Bone Formation of Adipose-Derived Stem Cell-Loaded and 3D-Printed Osteogenic Matrices in the Arteriovenous Loop Model. Tissue Eng Part A. 2020 Sep 18. doi: 10.1089/ten.TEA.2020.0087. 

11/30/2020
Abcell-bio is now part of the France Biotech network!

Abcell-bio is now part of the France Biotech network!

Biotechnology laboratory, Abcell-bio produces quality primary human cells from perinatal tissues. Our team is made up of dedicated scientists, whose objective is to facilitate the R&D work of our customers by forging real partnerships. As such, Abcell-bio is now part of the France Biotech network, whose role is to federate HealthTechs and MedTechs companies in France. The objective is to develop partnerships, private or public, in order to be more and more a player in the ecosystem of health innovation!

Would you like to develop a research partnership? Contact us, the scientific team will be delighted to answer your questions and support you in your projects.

11/15/2020
Which are the factors affecting human umbilical cord blood quality before cryopreservation?

Which are the factors affecting human umbilical cord blood quality before cryopreservation?

Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells (HSCs). Comparatively, UCB HSCs have an extensive proliferative capacity that exceeds that of bone marrow HSCs. However, the small quantity of HSCs obtained from an umbilical cord remains a problematic element restricting the usage of UCB and the quality of UCB units has to be checked before cryopreservation. This study aimed to determine the maternal and neonatal factors that influence UCB before selection for cryopreservation. The analysis included 403 processed UCB units. Neonates with higher birth weights produced better quality UCB units because of increased collected blood volumes, total nucleated cell counts, and CD34+ cell counts. However, an increase in the gestational age from 35 to 41 weeks led to decreases in the collected blood volume and CD34+ cell count.

As the specialist in the production of CD34+ progenitors from cord blood, Abcell-bio controls the collection and the selection of cord blood and guarantees you a number of CD34+ cells for each batch delivered. 

Nguyen PH, et al. Factors Affecting Human Umbilical Cord Blood Quality Before Cryopreservation: The Importance of Birth Weight and Gestational Age. Biopreserv Biobank. 2020;18(1):18-24. doi: 10.1089/bio.2019.0063. 

10/20/2020
Abcell-bio has obtained French Research Tax Credit (CIR) agreement

Abcell-bio has obtained French Research Tax Credit (CIR) agreement

For several years, Abcell-bio has been committed to its customers in order to facilitate their Research and Development projects. To go further, Abcell-bio has obtained the CIR agreement, which allows French companies to benefit from a tax credit on the expenses engaged in Research & Development or experimental procedures. It has been delivered by the French Ministry of Higher Education, Research & Innovation and it is valid for 3 years, until 2022. The basis for eligibility is an investment in research and development within the European Economic Area.

Please do not hesitate to contact us for any question, our scientific team is at your disposal.

10/14/2020
Human CD34 + Hematopoietic Stem Cell-Engrafted NSG Mice: Morphological and Immunophenotypic Features

Human CD34 + Hematopoietic Stem Cell-Engrafted NSG Mice: Morphological and Immunophenotypic Features

This study at characterizing the morphological phenotype of NSG mice and their humanized counterparts.  CD34+ hu-NSG murine model was generated via perinatal intrahepatic injection of human CD34+ fetal liver cells into NSG mice after preconditioning irradiation. Another purpose of this study was to assess the spectrum of histopathological lesions and identify the main causes of morbidity and mortality in young NSG mice and CD34+ HSC hu-NSG mice. Indeed, despite the increased popularity of these animal models in preclinical research, data on this topic are very sparse. The study describes the most common pathological features in young NSG mice after human hematopoietic stem cell engraftment. Mice frequently showed nephropathy, ovarian atrophy, cataract, and abnormal retinal development, lesions considered secondary to irradiation. In addition, 20% exhibited multisystemic granulomatous inflammatory infiltrates, dominated by human macrophages and T cells, leading to the observed 7% of mortality and morbidity. As some of these lesions contribute to morbidity, morphological assessment of the engraftment at tissue level might help improve immunophenotypic evaluations of this animal model. 

 

Blümich S, et al. Human CD34+ Hematopoietic Stem Cell-Engrafted NSG Mice: Morphological and Immunophenotypic Features. Vet Pathol. 2020 Sep 9:300985820948822. doi: 10.1177/0300985820948822. 

09/15/2020
Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells.

Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells.

Widely used for immuno-oncology studies evaluating new therapeutic agents, mice humanized with human tumors (CDX or PDX) and human immune system require carefully selected protocols. This review describes different protocols for establishing humanized mice from peripheral blood mononuclear cells (PBMC) or CD34+ hematopoietic stem cells from cord blood.As the specialist in the production of CD34+ progenitors from cord blood and PBMC, Abcell-bio is your partner to facilitate the production of your humanized mice and significantly enable your research.


Verma B, Wesa A. Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents. Curr Protoc Pharmacol. 2020 Jun;89(1):e77.